Abstract
The purpose of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of combined paclitaxel, epirubicin and cyclophosphamide in patients with metastatic breast cancer. The dose of paclitaxel was planned to be escalated from 150 to 225 mg/m<sup>2 </sup>in 25 mg/m<sup>2</sup> steps, while the doses of epirubicin and cyclophosphamide were fixed at 50 and 500 mg/m<sup>2</sup>, respectively. Because of DLT, the dose of paclitaxel was maintained at 200 mg/m<sup>2</sup> and the dose of epirubicin was increased to 90 mg/m<sup>2</sup>. The MTD was reached at a dose of paclitaxel and epirubicin of 200 and 75 mg/m<sup>2</sup>,<sup></sup>respectively. DLT were mainly febrile neutropenia and grade 4 neutropenia lasting for ≧7 days. Among the 35 evaluable patients, there were 2 (6%) complete responses and 19 (53%) partial responses for an overall response rate of 59% [95% confidence interval (CI): 41–74%]. The triplet paclitaxel/epirubicin/cyclophosphamide is an effective and well-tolerated combination worthy of further investigation in the treatment of patients with metastatic breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
